When was Quotient founded?

Quotient was founded in 2022 and raised its 1st funding round 1 year after it was founded.

Where is Quotient located?

Quotient is headquartered in Cambridge, United States.

How many employees does Quotient have?

As of Mar 31, 2026, the latest employee count at Quotient is 73.

Is Quotient a funded company?

Quotient is a funded company, having raised a total of $***** in its 1st and only funding round, a Series C round on Nov 22, 2023.

When was the latest funding round of Quotient?

Quotient's latest funding was a $***** Series C round on Nov 22, 2023, with participation from 1 investor. Its primary sector is Genomics. In United States, the Genomics sector has seen $424M in funding in 2026 to date.

Where does Quotient rank among its competitors?

Quotient ranks 89th amongst 527 active competitors, of which 195 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was Strand Therapeutics, which secured $153M in May, 2025.

Who are the top competitors of Quotient?

Quotient's top competitors include Alnylam, Sana Biotechnology and Spark Therapeutics. Among them, Strand Therapeutics secured the most recent funding round in May, 2025.

Quotient - 2026 Company Profile, Team, Funding & Competitors

Quotient is a series C company based in Cambridge (United States), founded in 2022 by Geoffrey Von Maltzahn. It operates as a Provider of somatic genomics platform to create transformational medicines. Quotient has raised $50M in funding from Flagship Pioneering. The company has 527 active competitors, including 195 funded and 129 that have exited. Its top competitors include companies like Alnylam, Sana Biotechnology and Spark Therapeutics.

Company Details

Provider of somatic genomics platform to create transformational medicines. The company is pioneering in the field of genetics with somatic genomics to unveil a universe of genetic information and develop transformative therapeutic possibilities.

Website: quotient-tx.com
Social
Email ID: *****@quotient-tx.com

Key Metrics

Founded Year

2022

Location

Cambridge, United States

Stage

Series C

Total Funding

$50M in 1 round

Latest Funding Round

Series C, Nov 22, 2023, $*****

Investors

Flagship Pioneering

Ranked

89^th among 527 active competitors

Employee Count

73 as on Mar 31, 2026

Similar Companies

Alnylam & 664 more

View Quotient's full profile

Quotient has raised a total funding of $50M over 1 round. Its latest funding round was a Series C round on Nov 22, 2023 for $*****. 1 investor participated in its latest round. Quotient has 1 institutional investor.

Here is the list of recent funding rounds of Quotient:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Nov 22, 2023	1634815	Series C	6722791	6283576	2813385	5520314

Access funding benchmarks and valuations. Sign up today!

View details of Quotient's funding rounds and investors

The founders of Quotient is Geoffrey Von Maltzahn.

Here are the details of Quotient's key team members:

Geoffrey Von Maltzahn: Founder of Quotient and founder of 6 other companies, including Tessera Therapeutics, Indigo and Sana Biotechnology.
Contact Info: 1 email address
Rahul Kakkar: CEO of Quotient.

View details of Quotient's Founder profiles and Board Members

Quotient's employee count trend

Quotient has 73 employees as of Mar 26. Here is Quotient's employee count trend over the years:

Uncover Quotient's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Quotient include Alnylam, Sana Biotechnology and Spark Therapeutics. Here is the list of Top 10 competitors of Quotient, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Alnylam 2002, Cambridge (United States), Public	Developer of RNA interference-based therapeutics for multiple disorders	$17M	Colt Ventures, BB Biotech & 13 others	79/100
2nd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of genetically engineered cell therapies for multiple disorders	$821M	Google Ventures, Baillie Gifford & 17 others	75/100
3rd	Spark Therapeutics 2013, Philadelphia (United States), Acquired	Developer of gene therapy for rare diseases	$82.8M	Sofinnova Investments, Brookside Capital & 6 others	73/100
4th	Fulcrum Therapeutics 2015, Cambridge (United States), Public	Developing small molecules for control mechanisms and genes regulation for the treatment of rare diseases	$115M	Google Ventures, Foresite Capital & 15 others	71/100
5th	Strand Therapeutics 2017, Cambridge (United States), Series B	Provider of platform to deliver mRNA therapeutics for multi functional treatments	$256M	Kinnevik, Playground Global & 19 others	70/100
6th	Insitro 2018, San Francisco (United States), Series C	Developer of machine learning platform for drug discovery and development	$643M	Andreessen Horowitz, Google Ventures & 18 others	70/100
7th	Forge Biologics 2020, Columbus (United States), Acquired	Developer of gene therapeutic solutions for treating multiple diseases	$330M	RA Capital Management, Aisling Capital & 7 others	70/100
8th	Passage Bio 2017, Philadelphia (United States), Public	Developer of gene therapies for CNS rare diseases	$226M	Access Biotechnology, Orbimed & 10 others	69/100
9th	Ultragenyx 2010, Novato (United States), Acquired	Developer of therapeutics for the treatment of rare and ultra-rare metabolic diseases	$135M	F-Prime Capital, Healthcap & 9 others	69/100
10th	Generation Bio 2016, Cambridge (United States), Acquired	Developer of gene therapies for rare liver and eye diseases	$236M	Fidelity Investments, T. Rowe Price & 9 others	69/100
89th	Quotient 2022, Cambridge (United States), Series C	Provider of somatic genomics platform to create transformational medicines	$50M	Flagship Pioneering	55/100